Zealand Pharma — Maj 2022
-
præcist..
-
Jeg synes ikke jeg kan se at short position over 0,5% er oeget paa det sidste. Den sidste aktivitet paa dette omraade var at World Quants reducerede deres short position i sidste uge. Saa det ser ikke ud til at det er store short positioner det store fald den sidste uges tid.
-
Om faldet i kursen kan forklares af det generelle fald i bioteksaktier er svaert at sige. Man kan jo ogsaa gisne om at de 2 storaktionaerer, Credit Suisse og The Capital Group, der er gaaet under 5% de sidste paa maaneder er dem der saelger ud. Den stoerste aktionaer, Van Herk, ser dog ud til at holde fast. Jeg mener at de havde oeget deres antal af aktier, da de sidst offentliggjorde deres position i Zealand tidligere paa aaret.
-
Nordnet
Tag kontrol over dine opsparinger. Invester i aktier, midler eller spar til din pension uden unødvendige gebyrer. Åbn konto i dag!
Nordnet (www.nordnet.dk)
-
Enig Exitnu og I Zealand har man en CEO der solgte sine aktier i det sene 2021
-
Enig Exitnu. Men det sender altid nogle signaler til markedet, såvel når CEO køber aktier, der kan tolkes positivt af positivt af markedet. Et salg i kurs 206 i september 2021, kan Hr. Steensberg da ikke være utilfreds med
-
+8% smuk begyndelse på en vending,,
-
Deal includes $10 million USD upfront payment to Zealand and sales-based milestones
Certain inventory related to V-Go
and employees also included under the terms of the deal
Agreement is part of Zealand’s refocused strategy to seek partners for commercial and late-stage assets while prioritizing research and development -
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
Company announcement – No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device Deal...
GlobeNewswire News Room (www.globenewswire.com)
-
du er så hurtig - tak
-
“This transaction is an important step forward in executing on the strategic refocusing we outlined at the end of March, as we find partners for our commercial and late-stage assets and prioritize the research and development of innovative new peptide therapeutics,” said Adam Steensberg, MD, Chief Executive Officer of Zealand Pharma. “We believe MannKind is the right partner to fully leverage the value of V-Go and ensure its continued availability for the patients and prescribers who need it.”
-
13%!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind